Source: Current Medicinal Chemistry. Conference titles: International Conference on Drug Discovery and Therapy. Unidades: FMRP, FFCLRP
Subjects: FARMACOLOGIA EXPERIMENTAL, RECEPTORES DE ENDORFINA, ANTAGONISTAS
ABNT
FELIPPOTTI, Tatiana Tocchini et al. Effect of a DAB-AM-16/naloxonazine nanocomplex on endogenous opioid peptides 'mü IND.1' receptor-mediated post-ictal antinociception. Current Medicinal Chemistry. Bussum: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. . Acesso em: 20 ago. 2024. , 2011APA
Felippotti, T. T., Carmo, D. R. do, Paim, L. L., Stradiotto, N. R., Bicalho, U. de O., Parada, C. A., et al. (2011). Effect of a DAB-AM-16/naloxonazine nanocomplex on endogenous opioid peptides 'mü IND.1' receptor-mediated post-ictal antinociception. Current Medicinal Chemistry. Bussum: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo.NLM
Felippotti TT, Carmo DR do, Paim LL, Stradiotto NR, Bicalho U de O, Parada CA, Grillo R, Fraceto LF, Coimbra NC. Effect of a DAB-AM-16/naloxonazine nanocomplex on endogenous opioid peptides 'mü IND.1' receptor-mediated post-ictal antinociception. Current Medicinal Chemistry. 2011 ; 144.[citado 2024 ago. 20 ]Vancouver
Felippotti TT, Carmo DR do, Paim LL, Stradiotto NR, Bicalho U de O, Parada CA, Grillo R, Fraceto LF, Coimbra NC. Effect of a DAB-AM-16/naloxonazine nanocomplex on endogenous opioid peptides 'mü IND.1' receptor-mediated post-ictal antinociception. Current Medicinal Chemistry. 2011 ; 144.[citado 2024 ago. 20 ]